Pain alleviation in diabetic neuropathy using hybrid closed loop insulin pumps (PAINLESS) – A randomised crossover trial protocol Authors: Simon Alexander Berry, Ahmed Iqbal, Jackie Elliott, Rajiv Gandhi, Abdul Paracha, Vaios Koutroukas, Mohummad Shaan Goonoo, Mahnoor Fatima Haq, Andrew Gerges, Gordon Sloan, Solomon Tesfaye, Pratik Choudhary, Dinesh Selvarajah, Yee Gary Ang, Yee Gary Ang, Yee Gary Ang Published: 2026 ABSTRACT IntroductionPainful diabetic neuropathy (PDN) is a common complication of diabetes that leads to significant co-morbidity. Emerging evidence suggests glycaemic variability may be linked to fluctuations in pain intensity. Hybrid closed loop (HCL) systems reduce glycaemic variability, raising the possibility that they may modify pain intensity. This study aims to evaluate the effects of HCL use on pain intensity in people with PDN.Materials and methodsPAINLESS is a two-centre, randomised cross-over study, recruiting 49 adults with type 1 diabetes and PDN. Each participant will complete two 12-week intervention periods in a randomised sequence (1:1): one with standard care including continuous glucose monitoring (CGM) and one with HCL using the Tandem t:slim X2 insulin pump with Control-IQ technology. The primary outcome is the change in 7-day average 24-hour pain intensity [rated on a numerical scale from 0-10 (NRS)] from baseline to the end of each 12-week intervention period as measured by daily pain diaries. Secondary outcomes include measures of pain trajectory/durability [responder rates (30% and 50% pain reduction in 7-day NRS), and the AUC for daily NRS scores], functional and quality of life outcomes [Short Form Health Survey (SF-36), and Short Form of the Brief Pain Inventory (BPI-MSF)], mood [Beck Depression Inventory (BDI)], health status [EQ-5D-5L], and global improvement [participant and clinician reported global impression of change]. Exploratory endpoints will harness neurophysiological assessments including Sudoscan, DPN-Check, Vagus and Vibrosense, and sleep and activity data from Withings devices. Statistical analyses will employ an intention-to-treat approach and mixed effect models.Timelines24-month trial: 18 months recruitment/follow up, 6 months close-out, analyses and dissemination.Registration DetailsISRCTN24233750. Introduction Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes [1]. Although DPN can be asymptomatic, up to one-third have painful diabetic neuropathy (PDN) [2]. This is a disabling condition with a profound impact on quality of life, sleep, and mental health [3]. Current pharmacotherapy offers limited efficacy and tolerability [4] with only 54% of patients achieving 50% pain relief on maximal combination therapy [5]. Options for ‘refractory’ neuropathic pain (NeuP) are limited. Opioids carry significant risks and offer no long-term benefit [6], while spinal cord neuromodulation is invasive, costly and unsuitable for many [7]. Other interventions lack robust evidence or availability [4], leaving a major unmet clinical need. Glycaemic variability (GV), reflecting fluctuations in glucose independent of overall glycaemic exposure, has been linked to fluctuations in pain intensity and has been identified as a potential modifiable therapeutic target [8]. Putative biological mechanisms to suggest the link between glycaemic variability and pathogenesis of diabetic neuropathy have been proposed, primarily via the induction of oxidative stress and systemic inflammatory responses [9]. Specifically, GV has been demonstrated to trigger the NF-kB and PKC pathways, leading to cellular damage that manifests as neuropathy. Continuous glucose monitoring (CGM) now allows precise measurement of GV, including coefficient variation (CV) and standard deviation of glucose (SD) [10]. A meta-analysis of 3,649 people with type 1 diabetes (pwT1D) and type 2 diabetes (T2D) demonstrated a two- to three-fold increased risk of DPN in those with higher GV [11]. Furthermore, GV has been specifically implicated in the development of painful over painless diabetic neuropathy [8,12]. Lower time in range (TIR), was significantly associated with an elevated risk and severity of PDN, independent of other risk factors [8]. However, whether reducing GV can directly modify pain intensity in PDN remains unknown. Hybrid closed loop (HCL) insulin delivery systems automate basal insulin dosing using CGM data and predictive algorithms [13]. Randomised controlled trials consistently show that HCL improves overall glycaemic control and reduces GV [14–17]. This raises the possibility that HCL could modify pain intensity in PDN by stabilising glucose fluctuations. The PAINLESS study is a two-centre, randomised cross-over trial designed to test this hypothesis. Adults with type 1 diabetes and PDN will receive 12-weeks of advanced HCL (Tandem t:slim X2 insulin pump with Control-IQ technology (Control-IQ)) and 12 weeks of standard care in randomised order. The primary outcome is the within-participant difference in 7-day average 24-hour pain on an 11-point numerical rating scale (NRS), consistent with IMMPACT recommendations for chronic pain trials [18]. Secondary outcomes include a core outcome set that will examine physical and emotional functioning and overall improvement. Finally, an embedded feasibility evaluation will assess acceptability, safety and operational considerations for future national health service roll-out. Materials and methods Trial design Each participant will complete a four-week screening period prior to a 24-week treatment period (Figs 1, 2). During screening, participants will complete daily sleep and pain diaries and wear CGM and an activity tracker. Participants with an average pain NRS ≥ 4 in the last 7 days, will be randomised (1:1 ratio) to begin either standard care with CGM or HCL insulin treatment for the first 12 weeks, followed by the alternative intervention for the second 12 weeks. No washout period is planned between intervention arms. Participant timeline: Schedule of enrolment, interventions, and assessments in Spirit 2025 Format [19]. The study is a randomised crossover design. Only Schedule A is illustrated. In Schedule B, after randomisation participants start at visit 3B and complete the comparator arm first (up to visit 6B), before switching to HCL start and completing visits 3A-7A. In this case, visit 7A is the study close-out for the participant. HCL – Hybrid Closed Loop. Flow Diagram of the PAINLESS Study. CGM – Continuous Glucose Monitoring, HCL Hybrid Closed Loop. Created in BioRender. Iqbal, A. (2026) https://BioRender.com/zh6dz7p. Eligibility criteria The PAINLESS study will recruit adults with type 1 diabetes who have experienced daily neuropathic pain for at least 3 months (Table 1). People with type 2 diabetes are not included as the pathophysiology of PDN differs, with greater influence of metabolic syndrome and dyslipidaemia [20]. Eligibility criteria were designed to exclude confounding conditions and mitigate potential barriers to HCL use. Co-enrolment of participants in observational studies is permitted but co-enrolment in other non-pain studies would require trial management group (TMG) approval. 10.1371/journal.pone.0357573.t001Table 1Inclusion and exclusion criteria.Inclusion criteria• Age > 18 years.• Clinical diagnosis of type 1 diabetes for at least 5 years [commenced on insulin treatment within one year of diagnosis].• Probable neuropathic pain > 3 months confirmed by IASP (NeupSIG) criteria.• Distal symmetrical polyneuropathy confirmed by the Toronto Clinical Neuropathy Score >5.• Douleur Neuropathique 4 score >4 at screening visit to confirm NeuP diagnosis.• HbA1c between 6.5 to 13% (47–118 mmol/mol).• No change to dose of neuropathic pain medication within the last month.• 7-day average pain NRS ≥ 4/10 during the final week of the Screening Period.• Willing and able to comply with the study schedule and be available for the treatment duration.• Able to give written informed consent. Exclusion criteria • Non-diabetic neuropathies.• Predominantly nociceptive, mixed or other more severe pain (unless transient) – to ensure diagnostic specificity, and avoid confounding, as mechanisms and response differ from NeuP.• Cognitive impairment or consent issues: to ensure ethical consent and valid, reliable self-report pain data.• Pregnancy/breast feeding or planning pregnancy during the course of the study.• Visual or hearing impairment, which would impede ability to use technological interventionsIASP – International Association for the Study of Pain; NeupSig – Neuropathic Pain Special Interest Group; NeuP – Neuropathic Pain; NRS – Numerical Rating Scale. Inclusion and exclusion criteria. IASP – International Association for the Study of Pain; NeupSig – Neuropathic Pain Special Interest Group; NeuP – Neuropathic Pain; NRS – Numerical Rating Scale. Study setting and recruitment To account for anticipated dropout and screen failure rate, the PAINLESS study will enrol approximately 49 participants in the screening period to achieve a randomised sample size of 40 participants in total across two research sites in the United Kingdom – Sheffield Teaching Hospitals National Health Service (NHS) Foundation Trust and University Hospitals of Leicester NHS Trust. The study recruited its first participant on 27th March 2026. Recruitment is ongoing with a planned recruitment period of 12 months, estimated to complete enrolment by 9th February 2027. Participants will be recruited from specialist PDN clinics, and their aligned primary care and podiatry services. Recruitment will be supported through digital promotion, including social media, and via local patient groups and charities. All study investigations and interventions will take place in clinical research facilities at the two sites. Data collection is expected to complete by September 2027 with results expected to be shared by February 2028. Standard of care in both arms HCL insulin therapy will be administered alongside standard care without requiring participants to stop their usual neuropathic pain medications. During the trial, minor adjustments to pain medication may occur at the clinician’s discretion to maintain safety and comfort, though further dose escalation is unlikely. All changes will be recorded and included in the analysis. Continuation of standard care is ethically and pragmatically justified, reflecting real-world practice, and facilitating recruitment as withholding standard neuropathic pain treatment would be unacceptable. Interventions Control intervention period: CGM only (Dexcom G7). In the control arm, participants will continue to use the insulin regimen on which they enter the study. As per NICE Quality Standard QS208, CGM is standard of care for pwT1D in the United Kingdom [21]. All participants will be provided with a Dexcom G7 continuous glucose monitoring (CGM) system. Standardisation of the CGM used enables comparison of glycaemic metrics between participants. The Dexcom G7 is a CE-marked device that is worn on the back of the upper arm, requiring replacement every 10 days with a 30-minute warm up period [22]. Participants will download the Dexcom G7 app onto their smartphones to enable cloud-based data sharing. Participants will receive formal instruction as per the device manual on how to use the Dexcom G7. During control arm visits, a diabetes clinician will review participants, analyse their glucose data, and provide advice on optimising insulin treatment and glycaemic management. Regular pain medication will be continued throughout the study with changes to neuropathic pain medication avoided where possible. All medication changes will be documented. HCL intervention period: HCL + CGM (t:slim X2 + Dexcom G7). At the start of the HCL intervention period, participants will attend an in-person training visit for instruction of use of the Control-IQ and a Dexcom G7 CGM, based on manufacturer guidelines. The t:slim X2 is a tethered insulin pump licensed in the UK for use with quick acting insulins (Humalog, NovoRapid, Lyumjev, Admelog, and Trurapi) [23]. Control-IQ is an advanced HCL algorithm that uses predictive technology to automatically modulate insulin delivery. It reduces or suspends basal insulin to mitigate impending hypoglycaemia and increases basal insulin delivery and administers automated correction boluses to address impending hyperglycaemia. The system also includes temporary modes for sleep and exercise that adjust glycaemic targets, and allows for the creation of multiple insulin profiles to accommodate different situations, such as illness. Comprehensive education will be provided on sick-day management, including protocols for preventing diabetic ketoacidosis and instructions to switch to back-up insulin pens in the event of pump malfunction or infusion set failure. The 12-week data collection period will commence after the training visit. All devices will be connected to the Tandem t:slim X2 mobile app to facilitate continuous cloud-based data upload. To ensure a safe transition to the new technology, a dedicated safety visit (Visit 3A) will be arranged shortly after the first scheduled infusion set change. At subsequent clinical visits, a diabetes clinician will review pump and CGM data, and provide advice to optimise pump settings. Concordance with hybrid closed loop treatment will be reviewed. The key therapeutic focus will be on improving glycaemic variability. To mitigate the risk of treatment-induced neuropathy of diabetes (TIND), a gradual reduction in average glucose levels will be implemented for participants with higher baseline HbA1c (>11.0%), by use of the pump in open loop mode for up to two weeks. A dedicated support number will be available for participants in all arms and sequences of the study. If ongoing treatment with HCL was deemed to be deleterious by the principal investigators, for example, due to worsening neuropathic pain, recurrent diabetic ketoacidosis, or any unforeseen recurrent or persistent issue, the trial participant would be returned to standard care. Outcomes. The primary outcome is the within-participant change in 7-day average 24-hour pain on an 11-point NRS from baseline to the end of each 12-week treatment period (sample pain diary in S2 File). A statistically significant reduction in the pain score will be considered to indicate superiority of the HCL treatment compared to standard care. This endpoint and measurement tool are considered the gold standard for clinical trials in PDN, aligning with the core domains of the IMMPACT consensus recommendations and NICE guidelines [18,24–26]. A 3-month endpoint is consistent with prior PDN studies, previously demonstrated to be a sufficient timeframe for clinical changes to be observed [27,28]. Secondary outcomes. While the primary outcome addresses the core IMMPACT domain of pain intensity, secondary outcomes are included to capture the other recommended domains of physical and emotional functioning, as well as patient global impression of change (Table 2). 10.1371/journal.pone.0357573.t002Table 2Pre-specified secondary outcomes.Pain-related outcomesProportion reaching 30% (moderate) and 50% (substantial) reduction in pain NRSChange in area under the curve (AUC) for all daily NRS scores (12-week intervention period)Changes in validated pain questionnaires:• Brief Pain Inventory (Modified Short Form) – BPI (MSF)• Neuropathic Pain Symptom Inventory (NPSI) Physical and emotional functioning Changes in validated questionnaires:• EQ-5D-5L• 36-Item Short Form Health Survey (SF-36)• Beck Depression Inventory (BDI)• Type 1 diabetes-specific distress (T1-DDS) Global impression of change Patient- and Clinician-rated Global Impression of Change (PGIC and CGIC) Glycaemic outcomes Key glycaemic metrics derived from CGM data, including time below range (TBR) <3.0 mmol/L, TBR 3–3.9 mmol/L, time in range (3.9–10 mmol/L), time in tight range (3.9–7.8 mmol/L), time above range >10–13.9 mmol/L, time above range >13.9 mmol/L, coefficient of variation (CV), standard deviation (SD), and Glucose Management Indicator (GMI)Haemoglobin A1c (HbA1c) Safety outcomes The frequency of adverse and serious adverse eventsNRS – Numerical Rating Scale. Time below range (TBR). Pre-specified secondary outcomes. NRS – Numerical Rating Scale. Time below range (TBR). Exploratory endpoints. Neurophysiological assessments will be performed to further understand the underlying mechanisms of painful diabetic neuropathy and the impact of glycaemic variability on these parameters. Sleep parameters and physical activity will be explored as an objective proxy of pain evolution and management. Validated hypoglycaemia questionnaires (HypoA-Q and Hypoglycaemia Confidence Scale (HCS)) will be completed at baseline and at the end of each treatment period to explore the relationship between hypoglycaemia and PDN. Participant timeline and data collection. A summary of key activities for study participants at each visit is summarised in Table 1. As per this schedule, some visits can be conducted remotely. Prior to participation, prospective participants will be provided with the participant information sheet and given the opportunity to ask questions (S3 File). Written informed consent will be obtained by the PI or delegate (S4 File). Re-consent will be obtained for any protocol amendments. 70% completion rate of pain and sleep diaries, and CGM data from the 4-week screening period will be required to be eligible for randomisation. A delay of three months from end of the four-week baseline data collection to start of the HCL twelve-week intervention period is permitted to allow scheduling of group starts. Three visits are scheduled during each 12-week intervention period to facilitate titration of treatment. Participants will continue to complete daily pain and sleep diaries until the end of the study. At the conclusion of each treatment arm, participants will attend a final visit for comprehensive data collection, including validated questionnaires (as listed in the secondary outcomes), a blood test for haemoglobin A1c, and neurophysiological assessments. Changes in level of participation within the trial are categorised in the following ways – no trial intervention, no trial related follow-up, and no further data collection – depending on the participant’s wishes. Where the participant consents, the participant will continue to attend the original schedule of assessments. Where they consent to data collection but do not wish to attend trial visits, where possible, data will be collected at standard clinic visits. Randomisation. Participants will be randomised at the level of the individual in a 1:1 ratio to either Treatment Sequence A (HCL + CGM followed by CGM only) or Treatment Sequence B (CGM only followed by HCL + CGM) using a secure online randomisation programme. The randomisation will use the Pocock-Simon minimisation algorithm to ensure balance in the treatment allocation taking into account centre, age (18–39, 40–59, 60+) and gender at birth [29]. Blinding (masking). Given the nature of the HCL intervention and the use of a visible device, it is not possible to blind participants to their assigned treatment arm. To mitigate potential bias from research staff, pain surveys are completed solely by the participants, with other secondary outcome assessments such as neurophysiological assessments and haemoglobin A1c yielding objective numerical data, which are not subject to assessor bias. Distress protocol. Given that some secondary outcome questionnaires assess sensitive topics such as depression and quality of life, there is a potential for participants to experience psychological distress. To mitigate this risk, a formal distress protocol is in place (S5 File). This includes providing immediate support from the trial clinician and a pre-established pathway for onward referral to a specialist mental health team if necessary. Neurophysiological tests. Four objective point-of-care neurophysiological assessments will be completed at baseline and at the end of each treatment period. The CE- and FDA-approved Sudoscan device (Impeto Medical ltd, Issy-les-Moulineaux, France) will be used to assess small-fibre neuropathy, based on sudomotor function. The test is a rapid and reproducible non-invasive assessment [30]. Participants place their hands and bare feet on electrode plates for 3 minutes. A low-voltage current (<4V) is applied to stimulate small fibres innervating sweat glands, and based on the electrochemical reaction between sweat chloride and stainless-steel electrodes, the resultant electrochemical skin conductance (ESC) is measured [31]. As per previous data, an ESC of <70 µS for Caucasian individuals and <60µS for Asian and African American individuals is considered diagnostic of DPN, whereas an ESC above these thresholds is considered normal [32]. The CE- and FDA-approved DPN-check (NeuroMetrix Inc, MA, USA), a handheld device with stimulating probes at one end and a biosensor at the other will be used to assess for large-fibre neuropathy [30,31]. The sural sensory nerve conduction velocity (SNCV;/m/s) and amplitude (sural nerve action potential (SNAP)) will be measured in both ankles, taking approximately 2 minutes. The device has an in-built infrared thermometer to measure skin temperature near the ankle, with subsequent SNCV readings normalised for skin temperature. DPN is associated with low SNAP and SNCV. The proprietary thresholds cut-offs for diagnosis of DPN using the DPN-Check are a SNAP ≤ 4 µV and/or SNCV ≤ 40 m/s in at least one leg. The DPN-Check’s software also provides an objective classification of neuropathy severity based on the measured SNCV and SNAP values, categorising the findings into four stages: 0 (Normal), 1 (Mild DPN), 2 (Moderate DPN), and 3 (Severe DPN). Vibration perception thresholds will be examined using multifrequency vibrometry via the VibroSense Meter II device (VibroSense Dynamics, Malmo, Sweden). The VibroSense Meter II tests vibration sensation at 4, 8, 16, 32, 64, 125 and 250 Hz at the right metatarsal head [33]. The examination is fully automated, with the vibration applied via a probe and the participant pressing down on a response button if they perceive vibration. Prior studies have demonstrated associations between deficits in vibration sensation and a higher risk of developing diabetic foot ulcers, gait or balance problems or weakness of the feet [34]. Autonomic function tests will be conducted with the Vagus Device (Medicus Engineering, Aarhus, Denmark), a handheld device, validated to diagnose autonomic neuropathy via two-electrode ECG recordings [35]. Assessment will comprise of two main components: time-domain and frequency-domain parameters from 5-minute resting heart rate variability; and four cardiac autonomic reflex tests (CARTs). The four standardised CARTs performed will be the expiration: inspiration (E:I) heart rate ratio during deep breathing, the heart rate response to a valsalva manoeuvre at 40 mmHg via a disposable mouthpiece, and both the heart rate and blood pressure response to standing. Results will be compared to published age- and sex-matched normative thresholds, with results below the 5th percentile deemed abnormal [35]. Activity and sleep tracking. Participants will be asked to use a Withings’ sleep tracker mat (Issy-les-Moulineaux, France) and an activity monitor watch during the study period. Sleep parameters collected will include total sleep time, sleep interruption, the apnoea-hypopnea index (AHI – a measure of sleep apnoea), nighttime heart rate and heart rate variability. Physical activity measures include active minutes, steps and skin temperature. These parameters will be used as exploratory objective proxy measures of pain evolution and management. Sample size justification. To detect a minimally important difference of 0.75 NRS points (between-patient SD of 2, within-participant SD = 1.44) with 90% power and two-sided α = 0.05, a crossover/pairwise comparison requires 39 evaluable participants. Allowing for 20% dropout during the eligibility screening period, we will recruit up to 49 participants. The 0.75-point NRS difference reflects a 15% reduction from a conservative baseline NRS of 5, consistent with IMMPACT guidelines which define a 15% between-group difference as clinically meaningful [18]. Calculations use the within-individual SD appropriate for crossover designs and therefore are conservative for detecting a true within-participant treatment effect. Using a lower baseline than typically seen in NeuP trials ensures the study is robustly powered, even in patients with milder pain (effect size 0.52). Our estimated dropout rates are conservative and allow for an increased dropout rate compared to previous HCL trials [14,16]. Data management. Sheffield Teaching Hospitals NHS Foundation Trust has policies in place which are designed to protect the security, accuracy, integrity and confidentiality of Personal Data. The trial will be registered with the Data Protection Officer and will hold data in accordance with the Data Protection Act (2018 and subsequent amendments). Personal details for each participant taking part in the study will be linked to a unique identification number held locally on a study screening log in the investigator site file at each site. All participant-related reports and communication transferred to the sponsor will be identified by this identification number only. User accounts for Dexcom clarity, Glooko and Tandem Connect will be pseudonymised, using the study identification number and a fake date of birth. Database lock will take place once all data entries have been checked and sufficient verification processes are completed. Reducing bias and ensuring objective assessment. Although participants and clinicians cannot be blinded to HCL use, we will minimise bias through several measures. Pain and sleep diaries collected from intervention visits will be analysed by an assessor blinded to treatment allocation. Analyses will be conducted by a statistician blinded to treatment sequence (the treatment sequence will be coded). Outcomes include objective metrics (CGM, activity logs) alongside standardised daily pain and sleep diaries. A pre-specified analysis plan and crossover design further reduce bias, with each participant serving as their own control. Independent oversight will monitor data quality and interpretation. Statistical analysis. The primary analysis will be conducted using an intention-to-treat (ITT) approach, including all participants who were randomized. As a preliminary step prior to the primary analysis, the change in the coefficient of variation (CV) between the control intervention period and HCL intervention period will be evaluated to assess intervention effect on glycaemic variability. The primary analysis will proceed regardless of whether a statistically significant difference in glucose CV is observed. A linear mixed-effects model will be used to assess the primary outcome, with all analysis performed by a statistician blinded to the allocation of treatment sequences. The model will include treatment arm, period, sequence, gender at birth, centre and age group as fixed effects and participant as a random effect to account for the repeated measures design. Model assumptions will be assessed using residual versus fitted plots and Q-Q plots of residuals. The NRS pain score (0–10) will be analysed as a continuous outcome, consistent with established practice in chronic pain trials. If model assumptions are violated, sensitivity analyses using alternative modelling approaches will be considered. The primary hypothesis will be tested at a two-sided significance level of α = 0.05. To minimise the risk of bias associated with missing data, a multiple imputation approach will be used as the primary method for handling missing NRS scores. This analysis will include all randomised participants. A participant’s NRS score will be considered missing if fewer than five daily pain scores are recorded in the final seven days of the treatment period. Sensitivity analyses will be conducted, including a per-protocol analysis, to evaluate the robustness of the primary findings. Secondary outcomes will be analysed, comparing changes from baseline to the end of the treatment period, between the two treatment arms. Exploratory analyses will examine the impact of the HCL system on objective neurophysiological assessments (Sudoscan, DPN-Check, Vibrosense and Vagus) by correlating changes in glycaemic metrics with changes in neurophysiological data; and examine how change in a participant’s NRS score correlate with physical activity and sleep parameters. Trial monitoring and management. Study monitoring will be conducted by the trial sponsor, Sheffield Teaching Hospitals NHS Foundation Trust, as per standard operating procedures. Authorised representatives of the sponsor or an ethics committee may perform audits or inspections at the recruiting centres, including source data verification. The trial will be overseen by an independent Data Monitoring Committee (DMC), which will be responsible for safeguarding the interests of trial participants, assessing the safety and efficacy data, and monitoring the overall conduct of the study. The reporting period for adverse events will be from the start of treatment until the end of trial follow-up. The recording and reporting of Adverse Events (AEs) will be in accordance with the UK Policy Framework for Health and Social Care Research, the Principles of Good Clinical Practice as set out in the UK Statutory Instrument (2004/1031; and subsequent amendments) and the requirements of the Health Research Authority (HRA). Post-trial care. At the last treatment visit, participants will be given advice on how to return to usual care. As per NICE TA943 [36], the majority of participants will be eligible for HCL continuation on the NHS. At present, NHS England plans to implement a roll-out of HCL to pwT1D meeting the eligibility criteria over 5 years [37]. Depending on the current guidance at the end of the study, HCL continuation will be facilitated wherever possible in collaboration with NHS services if the participant is eligible and has gained benefit from the treatment. Patient and public involvement statement. We thank the Lay Advice on Diabetes and Endocrine Research (LADDER) Panel in Sheffield, United Kingdom, for their invaluable input. The panel, which consists of patients, carers, and individuals with an interest in diabetes and endocrine conditions, have so far provided guidance on the study design, burden of interventions, and recruitment materials, with ongoing input planned for the future. Ethics and dissemination The study will be conducted in accordance with the Declaration of Helsinki Ethical Principles for Medical Research involving Human Subjects and in accordance with the UK Policy Framework for Health and Social Care Research and applicable UK Acts of Parliament and Statutory Instruments (and relevant subsequent amendments), which include Data Protection Act 2018; and the Principles of Good Clinical Practice as set out in the UK Statutory Instrument (2004/1031; and subsequent amendments). Ethical approval was obtained from Health Research Authority, Health and Care Research Wales and the West Midlands – Edgbaston Research Ethics Committee on 17th June 2025 (25/WM/0068). All participants will be provided with written information about the trial, including the procedures involved in the study before obtaining written informed consent. Any future non-substantial amendments will be managed by the sponsor and substantial amendments will be submitted to the Ethics Committee, with updates also made on the trial registry. Study results will be communicated directly to trial participants and disseminated through conference presentations and peer-review publications. Authorship eligibility will be assessed strictly according to ICMJE guidelines. Discussion The crossover design of this study allows for within-participant comparisons, reducing confounding and maximising data collection. By allowing each participant to serve as their own control, the study increases statistical power while ensuring ethical access to the HCL treatment for all study participants. Furthermore, the planned withdrawal of HCL in half of participants provides an opportunity to evaluate whether neuropathic pain returns to baseline levels following the intervention period. Despite these strengths, certain limitations are inherent to the study design. Due to the interactive nature of HCL, blinding participants to their treatment sequence is not feasible. There is also a risk of attrition bias, as the order of treatment may influence retention. For example, participants randomised to the intervention first might be more prone to dropping out before the crossover phase. TIND is a phenomenon in which rapid improvements in glycaemia can cause or accentuate painful diabetic neuropathy [38]. HCL has been demonstrated to achieve improvement in glycaemia [15], and a potential pitfall of the design is that a rapid improvement in glycaemia following HCL start might transiently worsen pain outcomes in some participants. To mitigate this risk, the protocol incorporates a two-week open loop period for participants with a high baseline HbA1c to ensure a more gradual transition. However, TIND could potentially act as a confounder or diluter of the primary outcome results. Conclusion The PAINLESS study is the first to evaluate the impact of HCL initiation on pain intensity in pwT1D and PDN. Through a robust randomised, crossover design this study will also capture comprehensive patient-centred outcomes including physical function, emotional well-being, quality of life and activity. If successful, this intervention offers a transformative prospect for patients, alleviating debilitating pain by optimising the management of the diabetes itself. Supporting information SPIRIT Checklist. The completed SPIRIT Checklist for the PAINLESS protocol. (DOCX) Pain and Sleep Diaries. The Pain and Sleep Diaries used in the PAINLESS study. (DOC) Participant Information Sheet (PIS). The Participant Information Sheet for the PAINLESS study. (DOCX) Consent form. The consent form used in the PAINLESS study. (DOCX) Distress Protocol – The protocol detailing the arrangements for managing potential distress that may be experienced by participants while completing questionnaires during research visits. (DOCX) Ethics board approved Protocol. (DOCX) 18 Jul 2026 Dear Dr. Berry, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 02 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Competing Interests section: " I have read the journal's policy and the authors of this manuscript have the following competing interests: S.B. has received charity-funded travel grants sponsored by Abbott and Eli Lilly. A.I. has received investigator-led funding from Dexcom and Abbott, and has received honoraria from Eli Lilly, Novo Nordisk, Sanofi, Boehringer Ingelheim, Ypsomed, and Diiachi Sankyo as speaker fees. J.E. has received educational / speaker fees from Abbott, Boehringer, Dexcom, Glooko, Insulet, Lilly, Medtronic, Novo Nordisk, Roche, Sanofi, and Ypsomed, and research support from Dexcom. V.K. has received a travel grant from KelCon GmbH, and has received charity-funded travel grants funded by Lilly. G.S has received honoraria from Procter and Gamble, Viatris, and Eli-Lilly. P.C. has received personal fees from Abbott Diabetes Care, Insulet, Dexcom, Novo Nordisk, AstraZeneca, Medtronic, Roche Diabetes Care, and Sanofi Diabetes, and research funding support from Abbott Diabetes Care, Medtronic, and Novo Nordisk. D.S. has received lecture honoraria from Wörwag Pharma and Grünenthal, unrestricted investigator led grant funding from Withings inc., Abbott Laboratories, Tandem Diabetes and Procter and Gamble, and is an executive committee member of the Novo Nordisk UK Research Foundation. A.P., A.G., R.G., S.M.G. and M.H. have no relevant disclosures to declare.” We note that one or more of the authors are employed by a commercial company: “Abbott, Eli Lilly, Dexcom, Novo Nordisk, Sanofi, Boehringer Ingelheim, Ypsomed, Diiachi Sankyo, KelCon GmbH, Procter and Gamble, Viatris, Abbott Diabetes Care, Insulet, AstraZeneca, Medtronic, Roche Diabetes Care, and Sanofi Diabetes, Wörwag Pharma and Grünenthal, Withings inc., Abbott Laboratories, Tandem Diabetes Novo Nordisk UK Research Foundation” 1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors “S.B., J.E., A.I., V.K., G.S., P.C., and D.S.,” but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. 3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement. 4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 5. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: We have invited multiple reviewers and 2 reviewers have responded with minor revision. Please see and resubmit if you are able to address the comments [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #1: This is a protocol of a crossover study. It is well-written and I have only some minor statistical comments: 1. Analysis will be conducted by a statistician blinded to treatment allocation. I'm not sure how a statistician can do an analysis of a treatment effect without including the treatment allocation in the analysis! 2. Minimization is a broad term that could include Taves's non-randomized procedure or Pocock-Simon's randomized procedure. You do not specify or provide a reference. See Rosenberger and Lachin (2016, Randomization in Clinical Trials, Chapter 9). 3. The general inference philosophy following minimization-type procedures is that the minimized variables should be included in the model to achieve valid inference (this is mentioned in the same chapter in the reference above). You do not seem to be doing this. 4. Random effects models are used with no description of the covariance structure, what diagnostics will be used to verify model assumptions, or what the underlying distribution of the outcome variable (NRS) is. 5. 49 seems an "odd" number for a 2 arm 1:1 clinical trial. I guess you can split one of the patients in half. Reviewer #2: In the protocol, use of a hybrid closed loop (HCL) system is compared with "standard care", which is the diabetes management used by the participant on entering the study. The eligibility and exclusion criteria do not exclude somebody from the study if they are already using a HCL system. Given the protocol is designed using the assumption that glycaemic variability will be less using an HCL system v standard care, why is this not excluded? Glycaemic variability will be compared between the groups using the measurement of percentage coefficient of variation (%CV), a standard continuous glucose monitoring (CGM) reporting measure. Why is the comparison of this measure between standard care and HCL use not more prominent in the analysis plan? It would seem that this should be carried out prior to other analyses, as if there is no difference in glycaemic variability between the conditions then the stated hypothesis cannot be tested. There may be other reasons that HCL treatment improves symptoms, and therefore the experiment remains valid even if this specific hypothesis is not tested directly, but that should be made clear. People with type 2 diabetes are excluded from this study. This should be justified directly, as there is evidence that HCL can improve gllycaemia in type 2 diabetes as well. I suspect the reason is that HCL treatment is currently funded in England under NICE TA 943 for eligible adults with type 1 diabetes and therefore there is the potential for participants to continue with the treatment after completion of the study, which would not currently be the case for type 2 diabetes. However, this should be made explicit. Note that the image of a CGM device included in the PIS is of a Dexcom G6 sensor - this should be replaced with an image of the correct sensor. Minro comment - introduction paragraph 2 line 68, the abbreviation pwT1D is used without explanation - this should be explained before abbreviation. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 24 Jul 2026 Reviewer #1: This is a protocol of a crossover study. It is well-written and I have only some minor statistical comments: 1. Analysis will be conducted by a statistician blinded to treatment allocation. I'm not sure how a statistician can do an analysis of a treatment effect without including the treatment allocation in the analysis! Many thanks for your constructive review. I will now address each comment point-by-point. The statistician will be blinded to the treatment allocation as each intervention will be given a code e.g. treatment A or treatment B. We have added this to the text lines 353 “Analyses will be conducted by a statistician blinded to treatment sequence (the treatment sequence will be coded)”. 2. Minimization is a broad term that could include Taves's non-randomized procedure or Pocock-Simon's randomized procedure. You do not specify or provide a reference. See Rosenberger and Lachin (2016, Randomization in Clinical Trials, Chapter 9). Thank you for pointing this out. The randomization procedure uses Pocock-Simon’s randomized procedure. On lines 259-260, the sentence now reads “The randomisation will use the Pocock-Simon minimisation algorithm to ensure balance in the treatment allocation taking into account centre, age (18-39, 40-59, 60+) and gender at birth [28]”. 3. The general inference philosophy following minimization-type procedures is that the minimized variables should be included in the model to achieve valid inference (this is mentioned in the same chapter in the reference above). You do not seem to be doing this. Thank you for this comment. We agree that variables used in the minimisation procedure should be included in the analysis model. We have clarified in the Methods that the primary analysis will be adjusted for centre, age group and gender at birth on lines 366-367 “The model will include treatment arm, period, sequence, gender at birth, centre and age group as fixed effects and participant as a random effect to account for the repeated measures design.” 4. Random effects models are used with no description of the covariance structure, what diagnostics will be used to verify model assumptions, or what the underlying distribution of the outcome variable (NRS) is. Thank you for this comment. We have expanded the statistical analysis section to describe the mixed-effects model in greater detail, including the covariance structure, the planned model diagnostic assessment and the rationale for treating the NRS score as a continuous outcome (lines 368-371). “Model assumptions will be assessed using residual versus fitted plots and Q-Q plots of residuals. The NRS pain score (0-10) will be analysed as a continuous outcome, consistent with established practice in chronic pain trials. If model assumptions are violated, sensitivity analyses using alternative modelling approaches will be considered.” 5. 49 seems an "odd" number for a 2 arm 1:1 clinical trial. I guess you can split one of the patients in half. Thank you for this comment. We have updated the description to explain that 49 is an approximate number for enrolment to achieve 40 randomised participants, accounting for dropout during the screening period (lines 127-128) “To account for anticipated dropout and screen failure rate, the PAINLESS study will enrol approximately 49 participants in the screening period to achieve a randomised sample size of 40 participants in total across two research sites in the United Kingdom – Sheffield Teaching Hospitals National Health Service (NHS) Foundation Trust and University Hospitals of Leicester NHS Trust.” Reviewer #2 In the protocol, use of a hybrid closed loop (HCL) system is compared with "standard care", which is the diabetes management used by the participant on entering the study. The eligibility and exclusion criteria do not exclude somebody from the study if they are already using a HCL system. Given the protocol is designed using the assumption that glycaemic variability will be less using an HCL system v standard care, why is this not excluded? Thank you for this comment and for pointing this out. To this date, no people already using HCL have enrolled in the study. However, we will incorporate a change in the exclusion criteria into an upcoming ethics amendment to exclude those already using HCL systems, only including those on multiple daily injections or open loop insulin pump systems. Glycaemic variability will be compared between the groups using the measurement of percentage coefficient of variation (%CV), a standard continuous glucose monitoring (CGM) reporting measure. Why is the comparison of this measure between standard care and HCL use not more prominent in the analysis plan? It would seem that this should be carried out prior to other analyses, as if there is no difference in glycaemic variability between the conditions then the stated hypothesis cannot be tested. There may be other reasons that HCL treatment improves symptoms, and therefore the experiment remains valid even if this specific hypothesis is not tested directly, but that should be made clear. Thank you for the comment. We agree that it is important to establish whether a change in glucose variability has been achieved. We will continue to analyse the results regardless of whether a change in glycaemic variability has been identified, in order to determine whether HCL treatment improves pain. To address this point in the manuscript, we have added the following to the description of the statistical analysis plan lines 360-364 “As a preliminary step prior to the primary analysis, the change in the coefficient of variation (CV) between the control intervention period and HCL intervention period will be evaluated to assess intervention effect on glycaemic variability. The primary analysis will proceed regardless of whether a statistically significant difference in glucose CV is observed.” People with type 2 diabetes are excluded from this study. This should be justified directly, as there is evidence that HCL can improve glycaemia in type 2 diabetes as well. I suspect the reason is that HCL treatment is currently funded in England under NICE TA 943 for eligible adults with type 1 diabetes and therefore there is the potential for participants to continue with the treatment after completion of the study, which would not currently be the case for type 2 diabetes. However, this should be made explicit. Thank you for the comment. The decision to focus on individuals with type 1 diabetes had two main reasons. One was a pragmatic decision based on licensing. At the time of planning this study, the tandem t:slim X2 was not licensed for people with type 2 diabetes in the United Kingdom (it was only approved in mid-2026). Secondly, the pathophysiology of painful peripheral neuropathy differs between those with type 1 and type 2 diabetes, with metabolic syndrome playing a more prominent role in type 2 diabetes and glucose excursions a more prominent role in type 1 diabetes. Therefore, people with type 1 diabetes hypothetically may benefit more when reducing glycaemic variability. As a result of the differing pathophysiology, we have chosen to keep a homogenous type 1 diabetes population rather than incorporating both type 1 and 2 in one study. We definitely agree that future research should also address this question in people with type 2 diabetes. For the readers, we have explicitly stated on lines 114-116 that people with type 2 diabetes are excluded “People with type 2 diabetes are not included as the pathophysiology of PDN differs, with greater influence of metabolic syndrome and dyslipidaemia [20].” Note that the image of a CGM device included in the PIS is of a Dexcom G6 sensor - this should be replaced with an image of the correct sensor. Thank you for pointing this out. The image has been updated and we will update the PIS in an ethics amendment. Minor comment - introduction paragraph 2 line 68, the abbreviation pwT1D is used without explanation - this should be explained before abbreviation. Thank you for raising this. The abbreviation has now been explained. Submitted filename: Response to reviewers.docx 19 Aug 2026 Pain Alleviation In diabetic Neuropathy using hybrid cLosEd Loop inSulin pumpS (PAINLESS) – A randomised crossover trial protocol PONE-D-26-29075R1 Dear Dr. Berry, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #1: All comments have been addressed, although I still don't understand why the study statistician needs to be blinded to treatment assignment. Won't he/she write the results section of your papers? How do you do that if you don't know which treatment is which? Overkill. Statisticians do not participate in patient recruitment and are bound by a code of ethics to not divulge anything during the trial. Reviewer #2: Many thanks for the opportunity to review the revised manuscript. My previous comments have been fully addressed. I just have a coupe of very minor comments on the revised draft. P5 line 75 – people with diabetes prefer us to avoid the term “glycaemic control” – please consider an alternative such a “glucose levels” or “glycaemia” P8 line 144 – Dexcom G7 is indicated for use on the abdomen as well as the upper arm in the UK ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** PONE-D-26-29075R1 PLOS One Dear Dr. Berry, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Yee Gary Ang Academic Editor PLOS One